Document:

<PAGE>

                                                                   Page 11 of 11

                                  EXHIBIT 4(a)

Item 4.  Ownership.

         The amounts set forth above give effect to the Agreement and Plan of
Reorganization (hereinafter referred to as the "Agreement") entered into as of
May 22, 2001 among Issuer, Comet Acquisition Corp., a Delaware Corporation and a
wholly owned subsidiary of Parent ("Merger Sub"), and C-Bridge Internet
Solutions, Inc., a Delaware Corporation (the "Seller"), whereby on September 19,
2001, the Merger Sub was merged with and into the Seller, the separate corporate
existence of the Merger Sub ceased and the Seller continued as the surviving
corporation. Pursuant to the Agreement, each share of common stock, par value
$.01, of the Seller (the "Seller Common Stock") issued and outstanding
immediately prior to September 19, 2001, subject to certain limitations
contained within the Agreement, was canceled and extinguished and automatically
converted into the right to receive (the "Right") 1.2517 shares of Common Stock,
par value of $.001 per share of Issuer ("Issuer Common Stock"), and said Right
was exercised immediately on September 19, 2001. Pursuant to the Agreement,
Insight Capital Partners III, L.P., a Delaware limited partnership ("Capital
Partners"), Insight Capital Partners III (Co-Investors), L.P., a Delaware
limited partnership ("Co-Investor Partners"), Insight Capital Partners (Cayman)
III. L.P., a Cayman Islands limited partnership ("Cayman Partners", together
with Capital Partners, Co-Investor Partners and Cayman Partners, "Insight III")
received 2,565,984 shares of Issuer Common Stock and Insight Venture Management,
Inc., a Delaware corporation ("Venture Management") received 31,292 shares of
Issuer Common Stock.

         On September 26, 2001, Insight III purchased an additional 700,000
shares of Issuer Common Stock in the aggregate, at a price per share of $0.50.
On September 28, 2001, InSight III purchased an additional 125,000 shares of
Issuer Common Stock in the aggregate, at a price per share of $0.47. For a more
detailed description of these transactions, please see the chart below.

<TABLE>
<CAPTION>
-------------------------------- ------------------------------ ----------------------------- -------------------------
            Entity                    Issuer Common Stock            Issuer Common Stock         Issuer Common Stock
                                           acquired                       acquired                    acquired
                                   pursuant to the Agreement             on 9/26/01                  on 9/28/01
-------------------------------- ------------------------------ ----------------------------- -------------------------
<S>                              <C>                            <C>                           <C>
Capital Partners                           1,803,216                        491,917                        87,842
-------------------------------- ------------------------------ ----------------------------- -------------------------

Co-Investor Partners                         316,079                         86,226                        15,398
-------------------------------- ------------------------------ ----------------------------- -------------------------

Cayman Partners                              446,689                        121,857                        21,760
-------------------------------- ------------------------------ ----------------------------- -------------------------

Venture Management                            31,292                        -------                        ------
-------------------------------- ------------------------------ ----------------------------- -------------------------

            Total:                         2,565,984                        700,000                       125,000
-------------------------------- ------------------------------ ----------------------------- -------------------------
</TABLE><PAGE>

                                                                   EXHIBIT 10.3

                TECHNOLOGY TRANSFER AND CUSTOM SERVICES AGREEMENT

THIS AGREEMENT made as of the 23 day of March, 2001.

BETWEEN:          MOLICHEM MEDICINES, INC., a corporation incorporated
                  under the laws of the North Carolina, USA and having a place
                  of business at:

                  207 South Elliott Road
                  PMB#231
                  Chapel Hill, NC
                  USA 27514

                  (hereinafter referred to as "MMI"

OF THE FIRST PART

                                    - and -

                  APOTEX FERMENTATION INC., a corporation incorporated
                  under the laws of Manitoba, Canada and having a place of
                  business at:

                  50 Scurfield Boulevard
                  Winnipeg, Manitoba
                  Canada R3Y 1G4

                  (hereinafter referred to as "AFI")

OF THE SECOND PART

WHEREAS AFI is engaged in the business of development and production of active
pharmaceutical raw materials and intermediates and possesses the necessary
know-how in research, development, scale up and manufacturing to provide
Services in respect of the Product to MMI (as described in Schedule "A" hereto);

AND WHEREAS MMI is the owner of or represents to have the appropriate license
and/or authority for the transfer of the necessary engineering, design, process
and operating information, technical data and other scientific and technical
information required to produce the Product;

                                      E-15

<PAGE>

AND WHEREAS MMI wishes to engage AFI and AFI wishes to accept such engagement to
provide the Services in respect of the Product at AFI's manufacturing facility
at 40 Scurfield Boulevard, Winnipeg, Manitoba (the '"Manufacturing Premises").

AND THEREFORE THIS INDENTURE WITNESSETH that in consideration of the payment
of two dollars ($2.00) by each of the parties hereto to the other party hereto,
the execution of this Agreement by the parties hereto, the mutual covenants and
conditions herein contained and other good and valuable consideration (the
receipt and sufficiency of which is hereby acknowledged by the parties), the
parties hereto do hereby covenant and agree as follows:

1.0      Upon the terms and conditions herein set forth, MMI hereby engages AFI
         (and AFI hereby accepts such engagement) to provide the Services in
         respect of the Product at the Manufacturing Premises in accordance with
         the Proposal attached as Schedule "A". MMI confirms that AFI is to
         proceed in accordance with Option #2 of the milestone payments program
         (Annex D of the Proposal). MMI shall have the exclusive right to
         acquire all the Product from AFI in accordance with the terms and
         conditions set out in Schedule "A".

2.0      Subject to paragraph 13 herein, the term of this Agreement shall be
         effective as of the date hereof and shall continue for the period until
         the Services in respect of the Product are fully delivered.

3.0      In consideration of the aforesaid services in Respect of the Product,
         MMI shall pay to AFI, the amounts set forth in Schedule "A" hereto upon
         the terms and conditions set out therein.

4.0      MMI shall provide to AFI all technical information and specifications
         on the Product required for manufacturing purposes as set out in
         Schedule "A" hereto at no cost to AFI. Nothing on this agreement shall
         be construed as a license to AFI for Moli1901 or the Product for any
         purpose other than as specifically set forth in this Agreement.

4.1      AFI shall supply raw materials for the manufacture of the Product as
         set out in Schedule "A" hereto.

5.0      AFI shall provide the Services in respect of the Product in compliance
         with MMI's Specifications and Methods as described in Schedule "A"
         hereto. Any changes to these Specifications and Methods must be
         notified to and approved by MMI in writing, prior to implementation.

5.1      AFI shall provide the Services in respect of the Product in accordance
         with the Good Laboratory Practice and Good Manufacturing Practices as
         commonly known and referred to in the industry.

6.0      In respect of delivery of the Product to MMI's premises (or to such
         other mutually agreed location) and by transportation mode mutually
         agreed between the parties, shipments will be made at the sole risk if
         AFI. Upon delivery by AFI of all or any part of the ordered Product to
         MMI's premises, the risk of loss or damage will pass from AFI to MMI.
         In the event of loss or damage to the Product during shipment, making
         the Product unusable for the intended

                                      E-16

<PAGE>

         purpose, AFI is responsible on a timely basis for the replacement of
         the Product only and not for any financial or other damages which may
         be suffered by MMI. MMI may at its option, arrange for its own
         insurance protection against loss or damage during shipment in which
         case MMI is to advise AFI of such an intention and AFI is to provide
         the necessary shipment information to allow the MMI insurance
         protection to be put in place.

7.0      MMI represents, warrants and covenants to AFI as follows and hereby
         acknowledges and agrees with AFI that AFI is relying on such
         representations, warranties and covenants in connection with the
         entering into by AFI of this Agreement:

         (a)      MMI is a subsisting corporation duly and validly incorporated
                  under the laws of the State of North Carolina, USA;

         (b)      the execution and delivery of this Agreement by MMI has been
                  duly authorized by all necessary corporate action and MMI has
                  all requisite corporate power and authority to enter into this
                  Agreement and to carry out the terms herein;

         (c)      this Agreement has been duly and validly executed and
                  delivered by MMI and constitutes a valid and legally binding
                  Agreement, enforceable against MMI;

         (d)      to the best of MMI's knowledge, the Services provided in
                  respect of the Product by AFI will not infringe upon the
                  intellectual property rights (i.e. patents and trademarks) of
                  any other parties.

         (e)      MMI is the legal and beneficial owner of the technical
                  specifications documented in Schedule "A" hereto, free and
                  clear of any claims of any nature or kind whatsoever of third
                  parties and has the absolute right, power and authority to
                  enter into this Agreement and to engage AFI for the Services
                  in respect of the Product as is contemplated herein;

         (f)      to do all things and cause all things to be done to ensure
                  that all of the representations, warranties and covenants of
                  MMI contained in this Agreement remain true and correct
                  throughout the term as if such representations and warranties
                  and covenants were continuously made throughout the term.

8.0      AFI represents, warrants and covenants as follows to MMI and hereby
         acknowledges and agrees that MMI is relying upon such representations,
         warranties and covenants in connection with the entering into by MMI of
         this Agreement;

         (a)      AFI is a subsisting corporation duly and validly incorporated
                  under the laws of the Province of Manitoba, Canada;

         (b)      the execution and delivery of this Agreement by AFI has been
                  duly authorized by all necessary corporate action and AFI has
                  all requisite corporate power and authority to enter this
                  Agreement and to carry out the terms herein;

                                      E-17

<PAGE>

         (c)      this Agreement has been duly and validly executed and
                  delivered by AFI and constitutes a valid and legally binding
                  agreement enforceable against AFI;

         (d)      the Product will be manufactured in compliance with and
                  meeting MMI's specifications as provided in Schedule "A"
                  hereto;

         (e)      AFI has the capability and capacity to provide the Services in
                  respect of the Product in accordance with MMI's specifications
                  as provided in Schedule "A" hereto;

         (g)      to do all things and cause all things to be done to ensure
                  that all of the representations, warranties and covenants of
                  AFI contained in this Agreement shall remain true and correct
                  throughout the terms as if such representations, warranties
                  and covenants were continuously made throughout the term.

9.0      AFI recognizes and acknowledges MMI's ownership and title to MMI's
         proprietary information and specifications and agrees to co-operate
         fully and in good faith with MMI and to execute such documents as MMI
         may reasonably request for the purposes of securing and preserving the
         rights of MMI in and to MMI's proprietary information as disclosed
         pursuant to this Agreement including, without limitation, MMI's
         specifications.

10.0     All copyrights, patents, trade secrets, or other intellectual property
         rights associated with any ideas, concepts, techniques, inventions,
         processes, or works of authorship developed or created by AFI during
         the course of performing the Services and related to Moli1901
         (collectively, the "Work Product") shall belong exclusively to MMI and
         shall, to the extent possible, be considered "works made for hire" for
         MMI. To the extent such work is determined not to constitute "works
         made for hire" as a matter of law, AFI hereby irrevocably assigns and
         transfers to MMI, as of the time of creation of the Work Product, any
         and all right, title, or interest it may have in such Work Product.

         Upon request of MMI and at MMI's expense, AFI shall take such further
         actions, including execution and delivery of instruments of conveyance
         necessary to obtain legal protection in the United States and foreign
         countries for such Work Product and for the purpose of vesting title
         thereto in MMI, or its nominee, as may be appropriate to give full and
         proper effect to such assignment and to vest in MMI complete title and
         ownership to such Work Product.

         Notwithstanding anything to the contrary herein, AFI shall be free to
         use and employ its general skills, know-how, and expertise, and to use,
         disclose, and employ any generalized ideas, concepts, know-how,
         methods, techniques or skills gained or learned during the course of
         this Agreement, so long as it acquires and applies such information
         without disclosure of any Confidential Information of MMI and without
         any unauthorized use of disclosure of Work Product.

11.0     All confidential records, material and information and copies thereof,
         and all trade secrets (and without restricting the generality of the
         foregoing any inventions, discoveries and methods of processing and
         production) concerning the business or affairs of obtained by MMI or of
         MMI obtained by AFI including, without limitation, MMI specifications
         and the

                                      E-18

<PAGE>
         terms and conditions of this Agreement, as a result of the entering
         into of this Agreement shall remain the exclusive property of the
         respective owner thereof. In order to preserve and protect the
         proprietary rights and any confidential information belonging to each
         of the parties thereto ("Confidential Information"), MMI and AFI agree
         that they will:

                  i.       treat and maintain the Confidential Information as
                           confidential both during the term, any renewal term
                           and thereafter;

                  ii.      use the Confidential Information only to fulfill its
                           obligations under this Agreement;

                  iii.     disclose the Confidential Information only as
                           necessary to its employees or agents who have a
                           demonstrable and valid "need to know" the
                           Confidential Information and not to anyone else;

                  iv.      disclose only so much of the Confidential Information
                           as is required to enable those employees or agents to
                           carry our their assigned duties; and

                  v.       advise its employees, agents or independent
                           contractors of the confidential nature of such
                           information and the requirements of non-disclosure.

         except if compelled to do so under Court Order of a competent authority
         (in such circumstance the party receiving the order will inform the
         other party prior to responding to the order).

11.1     For the purposes hereof, the Confidential Information includes
         information known or used by MMI or AFI in connection with their
         respective business, including, but not limited to any formula, design,
         prototype, compilation of information, data, program, code, method,
         technique or process, information relating to the Product or any other
         products, device, equipment or machine, information about or relating
         to MMI's or AFI's customers and MMI's or AFI's potential business
         ventures, financial information of all kinds relating to MMI or AFI and
         their respective activities, all inventions, ideas and related
         material, but does not include any of the foregoing which was known to
         MMI or AFI, as the case may be, prior to the entering into of this
         Agreement or which is or becomes a matter of public knowledge.

12.0     This Agreement is strictly personal to MMI and AFI. Neither this
         Agreement nor any of the rights granted hereunder including, without
         limitation, the right to use MMI'S specifications and the right to
         manufacture the Product shall be assignable or sub-licensed by MMI or
         AFI, by operation of law or otherwise.

13.0     If any one or more of the following events shall occur, AFI shall have
         the right to terminate this Agreement forthwith:

         (a)      MMI shall fail to pay any amounts payable hereunder within
                  thirty (30) days after the payment due date;

                                      E-19

<PAGE>

         (b)      MMI shall file a petition of bankruptcy, or shall be adjudged
                  a bankrupt, or a petition in bankruptcy shall be filed against
                  MMI and shall not be dismissed within thirty (30) days, or if
                  MMI shall become insolvent or shall discontinue its business;

         (c)      MMI shall disclose any information in respect to the
                  confidential information of AFI to any other party or shall
                  use any confidential information of AFI for any purpose other
                  than in relation to the provision of Services related to the
                  Product at the Premises; and

         (d)      MMI shall violate or fail to perform any of its other
                  undertakings, agreements, obligations, representations or
                  warranties under the terms of this Agreement and shall fail to
                  remedy any such breach within ten (10) days after AFI's notice
                  thereof.

13.1     If any one or more of the following events shall occur, MMI shall have
         the right to terminate this Agreement forthwith:

         (a)      AFI shall fail to pay any amounts payable hereunder within
                  thirty (30) days after the payment due date;

         (b)      AFI shall file a petition of bankruptcy, or shall be adjudged
                  a bankrupt, or a petition in bankruptcy shall be filed against
                  AFI and shall not be dismissed within thirty (30) days, or if
                  AFI shall become insolvent or shall discontinue its business;

         (c)      AFI shall disclose any information in respect to the
                  confidential information of MMI to any other party or shall
                  use any confidential information of MMI for any purpose other
                  than for the provision of Services related to the Product at
                  the Manufacturing Premises; and

         (d)      AFI shall violate or fail to perform any of its other
                  undertakings, agreements, obligations, representations or
                  warranties under the terms of this Agreement and shall fail to
                  remedy any such breach within ten (10) days after MMI's notice
                  thereof.

         (e)      MMI shall have the right to terminate the contract at the
                  completion of any milestone defined in Annex C (Schedule) of
                  the Proposal for the Production of Clinical Batches of
                  Moli1901. AFI shall not proceed to perform any work on the
                  milestone listed in Annex C without written authorization from
                  MMI and MMI shall have no financial obligation beyond approved
                  current milestones. In the event that MMI chooses to terminate
                  the contract at any time, AFI shall complete the work assigned
                  to the current milestone and shall be paid in full for the
                  milestone upon its completion. Termination of the contact or
                  authority to proceed shall be provided in writing within
                  fifteen (15) days of notification in writing by AFI of the
                  completion of a milestone.

13.2     Upon termination of this Agreement for cause, (a) AFI agrees to
         transfer and deliver to MMI immediately following the termination of
         this Agreement all documents, notebooks, charts, files and records
         containing or referencing MMI's Confidential Information (all
         confidential information) including copies, summaries, and notes in its
         possession or control and MMI

                                      E-20

<PAGE>

         Product and (b) MMI agrees to transfer and deliver to AFI immediately
         following the termination of this Agreement all documentation belonging
         to AFI in its possession.

13.3     The termination or expiration of this Agreement shall not relieve MMI
         or AFI from, or discharge, any obligations which accrued prior to such
         termination or expiration and shall not destroy or diminish the binding
         force and effect of any of the terms and conditions of this Agreement
         that expressly or by implication come into or continue in effect on or
         after termination or expiration.

13.4     Each of MMI and AFI acknowledge that the release or use of any of the
         Confidential Information other than as set out herein would be highly
         detrimental to the best interests of MMI or AFI, as the case may be,
         and that the right to maintain the confidentiality and ownership of the
         Confidential Information constitutes a proprietary right which MMI and
         AFI is entitled to protect. Any use of or any disclosure of the
         Confidential Information by MMI or AFI other than set out herein shall
         be deemed for all purposes to have caused the damaged party irreparable
         harm for which damages alone will not be adequate remedy and for which
         the damaged party shall be entitled to injunctive relief in addition to
         any other available remedies and MMI or AFI, as the case may be, hereby
         consents to the granting of an injunction to enforce the provisions of
         this Agreement and hereby waives any defenses AFI or MMI, as the case
         may be, may have in respect thereto.

14.0     Miscellaneous.

14.1     This Agreement (including the attached Schedule(s)) constitutes the
         entire Agreement between the parties with representations, warranties,
         covenants, agreements, or understanding relative thereto which are not
         set forth herein. No provision of this Agreement shall be effectively
         amended or waived except in writing signed by the party against whom
         the amendment or waiver is sought to be enforced.

14.2     Any notice or other communication required or permitted under this
         Agreement shall be in writing and may be given by personal delivery to
         the party for whom it is intended or by facsimile, or prepaid
         registered mail addressed:-

         in the case of MMI:

         MOLICHEM MEDICINES INC.
         207 South Elliot Road
         PMB#231
         Chapel Hill, NC
         USA 27514

         Attn:  Dr. Luis Molina, President and CEO

         Fax No:  919-929-3447

                                      E-21

<PAGE>

and in the case of AFI:

         APOTEX FERMENTATION INC.
         50 Scurfield Boulevard
         Winnipeg, Manitoba
         Canada R3Y 1G4

         Attn:  Gary Payne, General Manager and CEO

         Fax No:  204-989-9160

         In the event of a mail strike or other interruption of postal
         deliveries, all notices, directions or other instruments required or
         permitted to be given to the parties hereto shall be delivered or shall
         be sent by facsimile (receipt confirmed) to such parties.

         Any such notice or other communication given by delivery or facsimile
         shall be deemed to have been given on the day of delivery or facsimile
         or by prepaid mail twenty (20) days after mailing in Canada or the USA.
         Each party may at any time change its address for the purposes hereof
         by giving notice of such change to the others in accordance with the
         foregoing provisions.

14.3     Matters in dispute under this Agreement may, as agreed by the parties
         hereto, be referred to the arbitration.

14.4     Each of the parties hereto may extend the time for performance and
         waive non-performance by any of the other party hereto of its
         respective obligations and Agreements under this Agreement, but no act
         and/or failure to act by any of the parties shall be deemed to be an
         extension or waiver of timely and strict performance by the other
         parties to this Agreement of such obligations and Agreements, except to
         the extent notice is given to such of the other parties.

14.5     This agreement shall be governed by the laws of the state in the United
         States or the province of Canada of the defending party. Any provision
         herein which, in any way contravenes the laws of any jurisdiction or
         which is void, shall be deemed not to be part of this Agreement and
         shall be severable therefrom, and the remainder of the Agreement shall
         remain in full force and effect.

14.6     Article and Section headings contained in this Agreement are included
         solely for convenience, are not intended to be full or accurate
         descriptions of content thereof and shall not be considered part of
         this Agreement.

14.7     This Agreement shall extend to bind and enure to the benefit of the
         heirs, executors, administrators, successors and permitted assigns of
         the parties.

14.8     Nothing in this Agreement shall be deemed in any way or for any purpose
         to constitute any party a partner of the other party to the Agreement
         in the conduct of any business or

                                      E-22

<PAGE>

         otherwise or a member of a joint venture or joint enterprise with the
         other party to the Agreement.

14.9     AFI and MMI shall in a timely manner and as required from time to time
         take all such actions as may be necessary to give full effect to the
         provisions of this Agreement and abstain from taking any actions which
         would contravene the intent of the provisions of this Agreement and
         shall take all such actions, as may be necessary or appropriate to
         implement the transaction contemplated by this Agreement, including
         executing any appropriate documents or agreements.

14.10    AFI shall be excused for failure to perform any part of this Agreement
         due to events beyond its control. These events shall include but not be
         limited to fire, storm, flood, earthquake, explosions, embargoes, act
         of God and enactments of any acts or regulations or any priorities of
         any governmental authority.

14.11    This Agreement may be executed in counterpart.

14.12    Time shall be of the essence of this Agreement and every part hereof.

IN WITNESS WHEREOF the corporate parties hereto have set their hands and affixed
their corporate seals under the hands of their proper officers as of the date
first above written.

SIGNED, SEALED AND DELIVERED

In the presence of:       MOLICHEM MEDICINES INC.

                          Per: _______________________
                          Name:  Dr. Luis Molina
                          Title: President and EO

                          APOTEX FERMENTATION INC.

                          Per: __________________________
                          Name:  Gary Payne
                          Title: General Manager and CEO

                                      E-23

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]